Avastin Added To Tarceva/Gemcitabine Fails To Prolong Survival In Phase III Pancreatic Cancer Trial
This article was originally published in The Pink Sheet Daily
Roche-sponsored trial did not meet the primary endpoint of overall survival, but did show some clinical benefits.
You may also be interested in...
Pfizer VP and Oncology Therapeutic Head Charles Baum talks to “The Pink Sheet” DAILY in an exclusive interview about the pharma giant’s increasing research emphasis in cancer drugs, and about pipeline developments, including axitinib in pancreatic cancer and a CTLA4 inhibitor, tremelimumab, for melanoma.
Genentech and partner Roche await results from another first-line pancreatic cancer trial, AVITA, with enrollment slated to complete by year-end.
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.